Nykode Therapeutics AS (NYKD.OL) Stock Analysis & AI Equity Report
Nykode Therapeutics AS (NYKD.OL) overview
Nykode Therapeutics AS (NYKD.OL) stock analysis and AI equity research. For the latest completed financial year, 2025, Nykode Therapeutics AS reported revenue of USD 0m and operating profit of USD -29.9m; the year-end share price was 2.41 NOK and market capitalisation was NOK 787m. Nykode Therapeutics AS is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nykode Therapeutics AS's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About Nykode Therapeutics AS
Nykode Therapeutics is a clinical-stage biopharmaceutical company developing modular immunotherapy and vaccine candidates based on its Vaccibody platform. Its pipeline includes abi-suva, an off-the-shelf therapeutic vaccine for HPV16-positive cancers, and VB10.NEO, an individualized neoantigen vaccine for solid tumors. The company also pursues autoimmune programs and selective partnerships to advance development.
Generate the Nykode Therapeutics AS report
Nykode Therapeutics AS is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Nykode Therapeutics AS and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.